{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:07:59Z","timestamp":1773850079497,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13318-025-00955-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:35:29Z","timestamp":1751355329000},"page":"383-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of CYP3A5, ABCB1, and CYP2C8 Polymorphisms with Renal Function in Kidney Transplant Recipients Receiving Tacrolimus"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-1712","authenticated-orcid":false,"given":"Z\u00fchal","family":"Kaltu\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2162","authenticated-orcid":false,"given":"Nu\u015fin","family":"Harmanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-0866","authenticated-orcid":false,"given":"Garip","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7089-5418","authenticated-orcid":false,"given":"Engin","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"4","key":"955_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1472-8206.2007.00504.x","volume":"21","author":"RA Op den Buijsch","year":"2007","unstructured":"Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007;21(4):427\u201335.","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"955_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03461.x","volume":"68","author":"AF Hawwa","year":"2009","unstructured":"Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009;68(3):413\u201321.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"955_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1053\/j.ajkd.2019.01.031","volume":"73","author":"S Voora","year":"2019","unstructured":"Voora S, Adey DB. Management of KIDNEY transplant recipients by general nephrologists: core curriculum 2019. Am J Kidney Dis. 2019;73(6):866\u201379.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"955_CR4","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/pharmaceutics14102154","volume":"14","author":"M Miedziaszczyk","year":"2022","unstructured":"Miedziaszczyk M, Bajon A, Jakielska E, Primke M, Sikora J, Skowronska D, et al. Controversial interactions of tacrolimus with dietary supplements, herbs and food. Pharmaceutics. 2022;14(10):2154.","journal-title":"Pharmaceutics"},{"issue":"2","key":"955_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/00912700122009999","volume":"41","author":"I Bekersky","year":"2001","unstructured":"Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol. 2001;41(2):176\u201382.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"955_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/00912700122010104","volume":"41","author":"I Bekersky","year":"2001","unstructured":"Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41(3):289\u201397.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"955_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2165\/00002018-200225100-00003","volume":"25","author":"T van Gelder","year":"2002","unstructured":"van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25(10):707\u201312.","journal-title":"Drug Saf"},{"issue":"1","key":"955_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41598-025-85534-w","volume":"15","author":"M Miedziaszczyk","year":"2025","unstructured":"Miedziaszczyk M, Karczewski M, Idasiak-Piechocka I. The effect of the use of omeprazole versus famotidine on the kidney transplant function: a randomized controlled study. Sci Rep. 2025;15(1):1805.","journal-title":"Sci Rep"},{"issue":"2","key":"955_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12659\/AOT.883229","volume":"17","author":"VM Gijsen","year":"2012","unstructured":"Gijsen VM, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012;17(2):111\u201321.","journal-title":"Ann Transplant"},{"issue":"1","key":"955_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98(1):19\u201324.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"955_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"955_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1399-0012.2005.00370.x","volume":"19","author":"X Zhang","year":"2005","unstructured":"Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005;19(5):638\u201343.","journal-title":"Clin Transplant"},{"issue":"4","key":"955_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.transproceed.2018.02.032","volume":"50","author":"YY Htun","year":"2018","unstructured":"Htun YY, Swe HK, Saw TM. CYP3A5*3 genetic polymorphism and tacrolimus concentration in myanmar renal transplant patients. Transplant Proc. 2018;50(4):1034\u201340.","journal-title":"Transplant Proc"},{"issue":"4","key":"955_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/cts.12260","volume":"8","author":"C Jaja","year":"2015","unstructured":"Jaja C, Bowman L, Wells L, Patel N, Xu H, Lyon M, et al. Preemptive genotyping of CYP2C8 and CYP2C9 allelic variants involved in NSAIDS metabolism for sickle cell disease pain management. Clin Transl Sci. 2015;8(4):272\u201380.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"955_CR15","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1016\/j.transproceed.2018.06.040","volume":"50","author":"R Deng","year":"2018","unstructured":"Deng R, Liao Y, Li Y, Tang J. Association of CYP3A5, CYP2C8, and ABCB1 polymorphisms with early renal injury in chinese liver transplant recipients receiving tacrolimus. Transplant Proc. 2018;50(10):3258\u201365.","journal-title":"Transplant Proc"},{"issue":"2","key":"955_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481\u2013508.","journal-title":"Clin J Am Soc Nephrol"},{"key":"955_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/DDDT.S149340","volume":"12","author":"T Xia","year":"2018","unstructured":"Xia T, Zhu S, Wen Y, Gao S, Li M, Tao X, et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis. Drug Des Devel Ther. 2018;12:417\u201328.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"955_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FTD.0b013e3181e44244","volume":"32","author":"DA Hesselink","year":"2010","unstructured":"Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit. 2010;32(4):387\u201393.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"955_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1592\/phco.2005.25.6.779","volume":"25","author":"MS Joy","year":"2005","unstructured":"Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF. Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy. 2005;25(6):779\u201389.","journal-title":"Pharmacotherapy"},{"key":"955_CR20","first-page":"S11","volume":"65","author":"S Ernest","year":"1998","unstructured":"Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl. 1998;65:S11\u20137.","journal-title":"Kidney Int Suppl"},{"key":"955_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111233","volume":"126","author":"P Guo","year":"2024","unstructured":"Guo P, Zhang R, Zhou J, Li P, Liu Y, Shi S. Intracellular tacrolimus concentration correlates with impaired renal function through regulation of the IS-AHR-ABC transporter in peripheral blood mononuclear cells. Int Immunopharmacol. 2024;126: 111233.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"955_CR22","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1681\/ASN.2009020192","volume":"20","author":"M Naesens","year":"2009","unstructured":"Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20(11):2468\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"955_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513\u201322.","journal-title":"Curr Drug Metab"},{"key":"955_CR24","doi-asserted-by":"crossref","unstructured":"Yildirim E, Sahin G, Kaltus Z, Colak E. Effect of CYP3A5 and ABCB1 gene polymorphisms on tacrolimus blood concentration in renal transplant recipients. Clin Lab. 2019;65(11).","DOI":"10.7754\/Clin.Lab.2019.190343"},{"issue":"5","key":"955_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1053\/j.ajkd.2020.07.015","volume":"77","author":"MF Schneider","year":"2021","unstructured":"Schneider MF, Munoz A, Ku E, Warady BA, Furth SL, Schwartz GJ. Estimation of albumin-creatinine ratio from protein-creatinine ratio in urine of children and adolescents with CKD. Am J Kidney Dis. 2021;77(5):824\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"955_CR26","first-page":"118","volume":"44","author":"N Sakai","year":"2019","unstructured":"Sakai N, Fuchigami H, Ishizuka T, Tanaka T, Kato M, Nakamura T, et al. Relationship between a urine protein-to-creatinine ratio of 150 mg\/gram creatinine and dipstick grade in the health checkup: substantial number of false-negative results for chronic kidney disease. Tokai J Exp Clin Med. 2019;44(4):118\u201323.","journal-title":"Tokai J Exp Clin Med"},{"issue":"3","key":"955_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/cen.14849","volume":"98","author":"Y Nakano","year":"2023","unstructured":"Nakano Y, Murakami M, Hara K, Fukuda T, Horino M, Takeuchi A, et al. Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease. Clin Endocrinol (Oxf). 2023;98(3):323\u201331.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"955_CR28","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ckj\/sfab220","volume":"15","author":"AG Rinne","year":"2022","unstructured":"Rinne AG, Sorensen CA, Lima SL, Gil MG, Mena NN, Martin LD, et al. Early glomerular filtration rate changes in living kidney donors and recipients: an example of renal plasticity. Clin Kidney J. 2022;15(5):885\u201394.","journal-title":"Clin Kidney J"},{"issue":"5","key":"955_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/jhg.2015.12","volume":"60","author":"B Tavira","year":"2015","unstructured":"Tavira B, Gomez J, Diaz-Corte C, Coronel D, Lopez-Larrea C, Suarez B, et al. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients. J Hum Genet. 2015;60(5):273\u20136.","journal-title":"J Hum Genet"},{"issue":"2","key":"955_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/ndt\/gfp510","volume":"25","author":"LA Stevens","year":"2010","unstructured":"Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, et al. Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant. 2010;25(2):449\u201357.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"955_CR31","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s11255-017-1682-z","volume":"49","author":"M Raman","year":"2017","unstructured":"Raman M, Middleton RJ, Kalra PA, Green D. Estimating renal function in old people: an in-depth review. Int Urol Nephrol. 2017;49(11):1979\u201388.","journal-title":"Int Urol Nephrol"},{"issue":"4S","key":"955_CR32","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"10","key":"955_CR33","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1016\/j.transproceed.2019.08.030","volume":"51","author":"E Kwiatkowska","year":"2019","unstructured":"Kwiatkowska E, Kwiatkowski S, Wahler F, Gryczman M, Domanki L, Marchelk-Mysliwiec M, et al. C\/D ratio in long-term renal function. Transplant Proc. 2019;51(10):3265\u201370.","journal-title":"Transplant Proc"},{"issue":"5","key":"955_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1159\/000502290","volume":"44","author":"M Nowicka","year":"2019","unstructured":"Nowicka M, Gorska M, Nowicka Z, Edyko K, Edyko P, Wislicki S, et al. Tacrolimus: influence of the posttransplant concentration\/dose ratio on kidney graft function in a two-year follow-up. Kidney Blood Press Res. 2019;44(5):1075\u201388.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"955_CR35","first-page":"184","volume":"29","author":"MB Mulder","year":"2023","unstructured":"Mulder MB, van Hoek B, van den Berg AP, Polak WG, Alwayn IPJ, de Jong KP, et al. Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial. Liver Transpl. 2023;29(2):184\u201395.","journal-title":"Liver Transpl"},{"issue":"4","key":"955_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1432-2277.2012.01446.x","volume":"25","author":"G Gervasini","year":"2012","unstructured":"Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012;25(4):471\u201380.","journal-title":"Transpl Int"},{"issue":"10","key":"955_CR37","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1016\/j.transproceed.2010.09.052","volume":"42","author":"F Tinti","year":"2010","unstructured":"Tinti F, Mecule A, Poli L, Bachetoni A, Umbro I, Brunini F, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc. 2010;42(10):4047\u20138.","journal-title":"Transplant Proc"},{"issue":"6","key":"955_CR38","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000475888","volume":"45","author":"A Ferreira","year":"2017","unstructured":"Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, et al. Donor-specific anti-human leukocyte antigens antibodies, acute rejection, renal function, and histology in kidney transplant recipients receiving tacrolimus and everolimus. Am J Nephrol. 2017;45(6):497\u2013508.","journal-title":"Am J Nephrol"},{"key":"955_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.12659\/AOT.909036","volume":"23","author":"S Park","year":"2018","unstructured":"Park S, Kim YS, Lee J, Huh W, Yang CW, Kim YL, et al. Reduced tacrolimus trough level is reflected by estimated glomerular filtration rate (eGFR) changes in stable renal transplantation recipients: results of the OPTIMUM phase 3 randomized controlled study. Ann Transplant. 2018;23:401\u201311.","journal-title":"Ann Transplant"},{"issue":"1","key":"955_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/archdischild-2016-311062","volume":"102","author":"S Pasala","year":"2017","unstructured":"Pasala S, Carmody JB. How to use\u2026 serum creatinine, cystatin C and GFR. Arch Dis Child Educ Pract Ed. 2017;102(1):37\u201343.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"11","key":"955_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/FPC.0b013e32830e1e16","volume":"18","author":"HE Smith","year":"2008","unstructured":"Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics. 2008;18(11):943\u201353.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"955_CR42","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"955_CR43","doi-asserted-by":"publisher","unstructured":"Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. Transplant Proc. 2006;38(5):1290\u20132. https:\/\/doi.org\/10.1016\/j.transproceed.2006.02.079","DOI":"10.1016\/j.transproceed.2006.02.079"},{"issue":"7","key":"955_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","volume":"11","author":"D Dai","year":"2001","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11(7):597\u2013607.","journal-title":"Pharmacogenetics"},{"issue":"2","key":"955_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clpt.2004.04.006","volume":"76","author":"E Garcia-Martin","year":"2004","unstructured":"Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther. 2004;76(2):119\u201327.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"955_CR46","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.4238\/2013.July.8.7","volume":"12","author":"S Minhas","year":"2013","unstructured":"Minhas S, Setia N, Pandita S, Saxena R, Verma IC, Aggarwal S. Prevalence of CYP2C8 polymorphisms in a North Indian population. Genet Mol Res. 2013;12(3):2260\u20136.","journal-title":"Genet Mol Res"},{"issue":"7","key":"955_CR47","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1089\/gtmb.2011.0275","volume":"16","author":"K Pechandova","year":"2012","unstructured":"Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers. 2012;16(7):812\u20136.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"11","key":"955_CR48","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0006-2952(02)01354-0","volume":"64","author":"N Bahadur","year":"2002","unstructured":"Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64(11):1579\u201389.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"955_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/dmd.107.018010","volume":"36","author":"A Tornio","year":"2008","unstructured":"Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos. 2008;36(1):73\u201380.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"955_CR50","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2217\/pgs.09.82","volume":"10","author":"EB Daily","year":"2009","unstructured":"Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10(9):1489\u2013510.","journal-title":"Pharmacogenomics"},{"issue":"7","key":"955_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1389200220666190627101927","volume":"20","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zheng M, Yang H, Han Z, Tao J, Chen H, et al. Association of genetic variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with tacrolimus pharmacokinetics in renal transplant recipients. Curr Drug Metab. 2019;20(7):609\u201318.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"955_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/phar.1928","volume":"37","author":"FDV Genvigir","year":"2017","unstructured":"Genvigir FDV, Nishikawa AM, Felipe CR, Tedesco-Silva H Jr, Oliveira N, Salazar ABC, et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in brazilian kidney transplant recipients. Pharmacotherapy. 2017;37(5):535\u201345.","journal-title":"Pharmacotherapy"},{"issue":"5431","key":"955_CR53","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","volume":"285","author":"K Node","year":"1999","unstructured":"Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285(5431):1276\u20139.","journal-title":"Science"},{"issue":"10","key":"955_CR54","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1124\/dmd.30.10.1108","volume":"30","author":"I Koch","year":"2002","unstructured":"Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002;30(10):1108\u201314.","journal-title":"Drug Metab Dispos"},{"issue":"21","key":"955_CR55","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"955_CR56","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.clinthera.2010.11.010","volume":"32","author":"DR Kuypers","year":"2010","unstructured":"Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. Clin Ther. 2010;32(12):2012\u201323.","journal-title":"Clin Ther"},{"issue":"1","key":"955_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/FPC.0000000000000360","volume":"29","author":"R Hu","year":"2019","unstructured":"Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenet Genomics. 2019;29(1):9\u201317.","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"955_CR58","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","volume":"26","author":"F Glowacki","year":"2011","unstructured":"Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provot F, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26(9):3046\u201350.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"955_CR59","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.transproceed.2009.01.097","volume":"41","author":"JS Chen","year":"2009","unstructured":"Chen JS, Li LS, Cheng DR, Ji SM, Sun QQ, Cheng Z, et al. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus. Transplant Proc. 2009;41(5):1557\u201361.","journal-title":"Transplant Proc"},{"issue":"11","key":"955_CR60","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/00008571-200311000-00002","volume":"13","author":"MF Hebert","year":"2003","unstructured":"Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics. 2003;13(11):661\u201374.","journal-title":"Pharmacogenetics"},{"issue":"10","key":"955_CR61","first-page":"1965","volume":"62","author":"M Riegersperger","year":"2016","unstructured":"Riegersperger M, Plischke M, Steinhauser C, Jallitsch-Halper A, Sengoelge G, Winkelmayer WC, et al. The effect of ABCB1 polymorphisms on serial tacrolimus concentrations in stable austrian long-term kidney transplant recipients. Clin Lab. 2016;62(10):1965\u201372.","journal-title":"Clin Lab"},{"issue":"11","key":"955_CR62","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2217\/pgs-2018-0066","volume":"19","author":"L Yang","year":"2018","unstructured":"Yang L, de Winter BC, van Schaik RH, Xie RX, Li Y, Andrews LM, et al. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. Pharmacogenomics. 2018;19(11):895\u2013903.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"955_CR63","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2174\/138920009790711832","volume":"10","author":"XS Lai","year":"2009","unstructured":"Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab. 2009;10(9):1009\u201347.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"955_CR64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/01.tp.0000185305.63759.d3","volume":"81","author":"L Gallon","year":"2006","unstructured":"Gallon L, Akalin E, Lynch P, Rothberg L, Parker M, Schiano T, et al. ACE gene D\/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation. 2006;81(3):463\u20138.","journal-title":"Transplantation"},{"issue":"2","key":"955_CR65","doi-asserted-by":"publisher","first-page":"167","DOI":"10.33549\/physiolres.933332","volume":"66","author":"L Hoskova","year":"2017","unstructured":"Hoskova L, Malek I, Kopkan L, Kautzner J. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension. Physiol Res. 2017;66(2):167\u201380.","journal-title":"Physiol Res"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00955-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00955-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:03:14Z","timestamp":1757206994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00955-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00955-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Eskisehir Osmangazi University Scientific Research Projects Commission (19.0.9.2019\/48- ESOGU BAP: Project no. 2019\/2742).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors confirm that there are no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted after receiving approval from The Eskisehir Osmangazi University Non-interventional Clinical Research Ethics Committee granted approval for this study (permit no. 48\/19.09.2019).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Z.K., E.Y. and G.\u015e. defined the research question and developed the experimental protocols. Z.K. and N.H. performed all the experiments and analyzed the data. Z.K. drafted the manuscript. Z.K., E.Y. and G.\u015e. critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}